Brant Edward Isakson

Brant Edward Isakson

Auto-generated profile, based on publicly available information

Brant Edward Isakson

Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, Virginia, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2012 in Nature
Verified
Journal Article
Open access
PDF file
Adam C. StraubAdam C. Straub
Adam C. Straub
ALAlexander W. Lohman
Alexander W. Lohman
MBMarie Billaud
Marie Billaud
Scott Robert JohnstoneScott Robert Johnstone
Scott Robert Johnstone
SDScott T. Dwyer
Scott T. Dwyer
BIBrant E. Isakson
Brant E. Isakson
This study presents a new model for the regulation of nitric oxide signalling in endothelial cells; the oxidation state of endothelial haemoglobin α, controlled by cytochrome B5 reductase 3, regulates nitric oxide bioactivity and diffusion towards its vascular smooth muscle targets. This manuscript provides evidence for a new model of the regulation of nitric oxide signalling in myoendothelial gap junctions. The oxidation state of endothelial haemoglobin α, controlled by cytochrome b5 reductase 3, regulates nitric oxide bioavailability and diffusion towards its vascular smooth muscle targets by promoting either the formation of vasodilator S-nitrosothiols or the scavenging of nitric oxide. This endothelial regulation of nitric oxide modulates the effects of agents involved in the control of vascular tone, such as α-adrenergic agonists or substances that evoke endothelium-dependent relaxations. Models of unregulated nitric oxide (NO) diffusion do not consistently account for the biochemistry of NO synthase (NOS)-dependent signalling in many cell systems1,2,3. For example, endothelial NOS controls blood pressure, blood flow and oxygen delivery through its effect on vascular smooth muscle tone4, but the regulation of these processes is not adequately explained by simple NO diffusion from endothelium to smooth muscle3,5. Here we report a new model for the regulation of NO signalling by demonstrating that haemoglobin (Hb) α (encoded by the HBA1 and HBA2 genes in humans) is expressed in human and mouse arterial endothelial cells and enriched at the myoendothelial junction, where it regulates the effects of NO on vascular reactivity. Notably, this function is unique to Hb α and is abrogated by its genetic depletion. Mechanistically, endothelial Hb α haem iron in the Fe3+ state permits NO signalling, and this signalling is shut off when Hb α is reduced to the Fe2+ state by endothelial cytochrome b5 reductase 3 (CYB5R3, also known as diaphorase 1)6. Genetic and pharmacological inhibition of CYB5R3 increases NO bioactivity in small arteries. These data reveal a new mechanism by which the regulation of the intracellular Hb α oxidation state controls NOS signalling in non-erythroid cells. This model may be relevant to haem-containing globins in a broad range of NOS-containing somatic cells7,8,9,10,11,12,13.

6 September 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
KBKanchan Bisht
Kanchan Bisht
KOKenneth A. Okojie
Kenneth A. Okojie
KSKaushik Sharma
Kaushik Sharma
DLDennis H. Lentferink
Dennis H. Lentferink
YSYu-Yo Sun
Yu-Yo Sun
UEUkpong B. Eyo
Ukpong B. Eyo
Microglia are brain-resident immune cells with a repertoire of functions in the brain. However, the extent of their interactions with the vasculature and potential regulation of vascular physiology has been insufficiently explored. Here, we document interactions between ramified CX3CR1 + myeloid cell somata and brain capillaries. We confirm that these cells are bona fide microglia by molecular, morphological and ultrastructural approaches. Then, we give a detailed spatio-temporal characterization of these capillary-associated microglia (CAMs) comparing them with parenchymal microglia (PCMs) in their morphological activities including during microglial depletion and repopulation. Molecularly, we identify P2RY12 receptors as a regulator of CAM interactions under the control of released purines from pannexin 1 (PANX1) channels. Furthermore, microglial elimination triggered capillary dilation, blood flow increase, and impaired vasodilation that were recapitulated in P2RY12−/− and PANX1−/− mice suggesting purines released through PANX1 channels play important roles in activating microglial P2RY12 receptors to regulate neurovascular structure and function.

7 June 2012 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
ALAlexander W. Lohman
Alexander W. Lohman
MBMarie Billaud
Marie Billaud
BIBrant E. Isakson
Brant E. Isakson
The nucleotide adenosine 5′-triphosphate (ATP) has classically been considered the cell's primary energy currency. Importantly, a novel role for ATP as an extracellular autocrine and/or paracrine signalling molecule has evolved over the past century and extensive work has been conducted to characterize the ATP-sensitive purinergic receptors expressed on almost all cell types in the body. Extracellular ATP elicits potent effects on vascular cells to regulate blood vessel tone but can also be involved in vascular pathologies such as atherosclerosis. While the effects of purinergic signalling in the vasculature have been well documented, the mechanism(s) mediating the regulated release of ATP from cells in the blood vessel wall and circulation are now a key target of investigation. The aim of this review is to examine the current proposed mechanisms of ATP release from vascular cells, with a special emphasis on the transporters and channels involved in ATP release from vascular smooth muscle cells, endothelial cells, circulating red blood cells, and perivascular sympathetic nerves, including vesicular exocytosis, plasma membrane F1/F0-ATP synthase, ATP-binding cassette (ABC) transporters, connexin hemichannels, and pannexin channels.

1 September 2018 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
IBIsola A.M. Brown
Isola A.M. Brown
LDLukas Diederich
Lukas Diederich
MGMiranda E. Good
Miranda E. Good
LDLeon J. DeLalio
Leon J. DeLalio
SMSara A. Murphy
Sara A. Murphy
BIBrant E. Isakson
Brant E. Isakson
Cardiovascular disease is a leading cause of death worldwide and accounts for >17.3 million deaths per year, with an estimated increase in incidence to 23.6 million by 2030.1Cardiovascular death represents 31% of all global deaths2—with stroke, heart attack, and ruptured aneurysms predominantly contributing to these high mortality rates. A key risk factor for cardiovascular disease is hypertension. Although treatment or reduction in hypertension can prevent the onset of cardiovascular events, existing therapies are only partially effective. A key pathological hallmark of hypertension is increased peripheral vascular resistance because of structural and functional changes in large (conductive) and small (resistance) arteries. In this review, we discuss the clinical implications of vascular remodeling, compare the differences between vascular smooth muscle cell remodeling in conductive and resistance arteries, discuss the genetic factors associated with vascular smooth muscle cell function in hypertensive patients, and provide a prospective assessment of current and future research and pharmacological targets for the treatment of hypertension.

14 September 2021 in Circulation
Verified
Journal Article
Open access
PDF file
FLFrancesca Leo
Francesca Leo
TSTatsiana Suvorava
Tatsiana Suvorava
SHSophia K. Heuser
Sophia K. Heuser
JLJunjie Li
Junjie Li
ALAnthea LoBue
Anthea LoBue
MCMiriam M. Cortese-Krott
Miriam M. Cortese-Krott
Background: Current paradigms suggest that nitric oxide (NO) produced by endothelial cells (ECs) through endothelial nitric oxide synthase (eNOS) in the vessel wall is the primary regulator of blood flow and blood pressure. However, red blood cells (RBCs) also carry a catalytically active eNOS, but its role is controversial and remains undefined. This study aimed to elucidate the functional significance of RBC eNOS compared with EC eNOS for vascular hemodynamics and nitric oxide metabolism. Methods: We generated tissue-specific loss- and gain-of-function models for eNOS by using cell-specific Cre-induced gene inactivation or reactivation. We created 2 founder lines carrying a floxed eNOS (eNOS flox/flox ) for Cre-inducible knockout (KO), and gene construct with an inactivated floxed/inverted exon (eNOS inv/inv ) for a Cre-inducible knock-in (KI), which respectively allow targeted deletion or reactivation of eNOS in erythroid cells (RBC eNOS KO or RBC eNOS KI mice) or in ECs (EC eNOS KO or EC eNOS KI mice). Vascular function, hemodynamics, and nitric oxide metabolism were compared ex vivo and in vivo. Results: The EC eNOS KOs exhibited significantly impaired aortic dilatory responses to acetylcholine, loss of flow-mediated dilation, and increased systolic and diastolic blood pressure. RBC eNOS KO mice showed no alterations in acetylcholine-mediated dilation or flow-mediated dilation but were hypertensive. Treatment with the nitric oxide synthase inhibitor N γ -nitro- l -arginine methyl ester further increased blood pressure in RBC eNOS KOs, demonstrating that eNOS in both ECs and RBCs contributes to blood pressure regulation. Although both EC eNOS KOs and RBC eNOS KOs had lower plasma nitrite and nitrate concentrations, the levels of bound NO in RBCs were lower in RBC eNOS KOs than in EC eNOS KOs. Reactivation of eNOS in ECs or RBCs rescues the hypertensive phenotype of the eNOS inv/inv mice, whereas the levels of bound NO were restored only in RBC eNOS KI mice. Conclusions: These data reveal that eNOS in ECs and RBCs contribute independently to blood pressure homeostasis.

5 August 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
ALAlexander W. Lohman
Alexander W. Lohman
ILIgor L. Leskov
Igor L. Leskov
JBJoshua Butcher
Joshua Butcher
Scott Robert JohnstoneScott Robert Johnstone
Scott Robert Johnstone
TSTara A. Stokes
Tara A. Stokes
BIBrant E. Isakson
Brant E. Isakson
Inflammatory cell recruitment to local sites of tissue injury and/or infection is controlled by a plethora of signalling processes influencing cell-to-cell interactions between the vascular endothelial cells (ECs) in post-capillary venules and circulating leukocytes. Recently, ATP-sensitive P2Y purinergic receptors have emerged as downstream regulators of EC activation in vascular inflammation. However, the mechanism(s) regulating cellular ATP release in this response remains elusive. Here we report that the ATP-release channel Pannexin1 (Panx1) opens downstream of EC activation by TNF-α. This process involves activation of type-1 TNF receptors, recruitment of Src family kinases (SFK) and SFK-dependent phosphorylation of Panx1. Using an inducible, EC-specific Panx1 knockout mouse line, we report a previously unidentified role for Panx1 channels in promoting leukocyte adhesion and emigration through the venous wall during acute systemic inflammation, placing Panx1 channels at the centre of cytokine crosstalk with purinergic signalling in the endothelium.